Great Lakes Pharmaceuticals (GLPI) has selected OmniComm Systems' TrialMaster suite of applications to support clinical research needs for a multi-national pivotal device study involving up to 400 subjects across 20 sites.
OmniComm will build and host the study for GLPI by installing TrialMaster for electronic data capture.
With the eLearning system, OmniComm will train more than 60 site users for the study and its EDC technology will help the GLPI to manage its complex clinical trial.
OmniComm chief executive officer Krzysztof Applet said Great Lakes Pharmaceuticals chose TrialMaster because it is a very straight-forward, configurable system with robust reporting capabilities.
Source:
http://itsoftware.pharmaceutical-business-review.com/news/glpi-selects-omnicomm-trialmaster-suite-for-pivotal-device-study-110412